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To investigate the prevalence of, and risk factors for, cervical infection with human papillomavirus (HPV) in the rural province of
Shanxi, People’s Republic of China, which has relatively high cervical cancer mortality rates, we interviewed and obtained cervical cell
samples from 662 women aged 15–59 years. A total of 24 different HPV types were identified using a GP5þ/6þ-based PCR assay
able to detect 44 different HPV types. Human papillomavirus prevalence was 14.8% overall and 9.6% among women without cervical
abnormalities (14.2 and 8.9%, respectively, age standardised to the world standard population). Multiple-type infections accounted for
30.6% of all infections. By far the most commonly found type was HPV16 (5.7% of all women and 38.8% of HPV-positive women),
followed by HPV 58, 52, 33 and 18. Unlike most previous studies published, HPV prevalence was lower among women younger than
35 years (8.7%) than those older than 35 years (17.8%). High-risk HPV types predominated in all age groups. Although low-risk HPV
types were rare in young women, they became more common with increasing age. 92.3% of women with cervical intraepithelial
neoplasia grade 3 were infected with high-risk HPV types, but none with low-risk types only. No significant difference in HPV
positivity was observed by educational level, sexual habits, reproductive history or use of contraceptive methods in this rural low-
income Chinese population.
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Following acceptance of human papillomavirus (HPV) as a
necessary cause of cervical cancer, primary and secondary cervical
cancer prevention strategies have moved towards detection and
control of the virus. In order to understand the potential impact of
HPV vaccination and HPV-based screening, epidemiological data
on HPV type-specific prevalence among women from different
populations is important. The International Agency for Research
on Cancer (IARC) has therefore carried out surveys in representa-
tive samples of women worldwide (Jacobs et al, 2000; Lazcano-
Ponce et al, 2001; Molano et al, 2002; Anh et al, 2003; de Sanjose ´
et al, 2003; Matos et al, 2003; Shin et al, 2003; Sukvirach et al, 2003;
Ferreccio et al, 2004; Shin et al, 2004; Thomas et al, 2004;
Franceschi et al, 2005; Ronco et al, 2005). These surveys have
disclosed wide variations in HPV prevalence and some in the
relative frequency of individual HPV types (Clifford et al, 2005).
The population of the People’s Republic of China is 1.3 billion,
of which 0.9 billion is rural. According to data from a network of
10 Chinese cancer registries, cervical cancer incidence in China is
estimated to be below 4/100000 (Parkin et al, 2002). However,
nationwide mortality surveys show a heterogeneous pattern of
cervical cancer risk, with particularly high rates in central rural
provinces (Yang et al, 2003a). Furthermore, while cervical cancer
mortality appears to have declined considerably in urban China
between 1987 and 1999, this is less marked in rural areas (Yang
et al, 2003b). A recent study in one such high-risk rural area,
Shanxi Province, revealed that 23.6% of women aged 35–50 years
were infected with high-risk HPV types (Zhao et al, 2006).
However, at present no population-based data are available on
HPV prevalence across a broader age range of Chinese women, nor
on the relative frequency of individual HPV types.
MATERIALS AND METHODS
Study subjects
This study was a collaborative project between the IARC and the
Cancer Institute of the Chinese Academy of Medical Sciences (CI-
CAMS) and study methods were similar to those used for previous
IARC HPV prevalence surveys (Clifford et al, 2005). The study area
of Shanxi Province is a rural, mountainous area in central China,
with a population mainly employed in agriculture and mining.
A total of 2229 women aged 15–59 years were enumerated in
March and April 2004 from the population list of eight randomly
chosen villages in Hebei Commune, Yangcheng County, Shanxi
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yProvince, China. The study purpose was to enroll approximately
100 women in each 5-year age group between 15–19 and 55–59
years. Women were contacted at their home by village doctors and
invited to Yangcheng Tumour Hospital to participate in the study.
All mentally and physically competent women aged 15–59 years
were eligible for the study. Women were interviewed regardless
of their marital status but pelvic examination and cervical cell
specimen collection were only possible among married women.
Of the 2229 enumerated women, 157 were not found at the
address given on the population list, and 404 were not invited as
the required sample size for their age group had been reached.
Of the 1668 invited women, 727 (43.6%) did not participate in
the study, mainly because they said they did not have time or
did not understand the need to undergo gynaecological examina-
tion in the absence of symptoms. Of the remaining 941 women
who participated between May and June 2004, 197 did not give
a cervical cell specimen (159 unmarried, 13 pregnant, nine
menstruating, and three hysterectomised women, as well as 13
married women who opted not to undergo pelvic examination).
The interview was administered by one of four research nurses
in the Shanxi dialect of Chinese. The structured questionnaires
included information on socio-demographic characteristics, re-
productive and menstrual factors, sexual habits of women and
their husbands, and lifetime use of contraceptive methods.
All participants signed an informed consent form according to
the recommendations of the IARC and CI-CAMS ethical review
committees, which approved the study.
Gynaecological examination and cervical specimen
collection
A total of 744 married women underwent a pelvic examination by
one of four gynaecologists. Firstly, a sample of exfoliated cervical
cells for liquid-based cytology and HPV testing was collected. A
cytobrush was inserted into the endocervical canal and rotated
gently 180
o in order to collect cells from the endo- and ectocervix.
The brush containing cellular material was then placed in a vial
containing CytoRich transport media (Tripath Imaging, Burlington,
NC, USA). Two aliquots of cellular material were obtained in the
CI-CAMS laboratory using a strict protocol to minimise conta-
mination, and were then sent to IARC for HPV testing. Remaining
cellular material was used to perform liquid-based cytology at CI-
CAMS. Secondly, the cervix was inspected by visual inspection with
acetic acid (VIA) and visual inspection with Lugol’s Iodine solution
(VILI), followed by a digital colposcopy. Women with suspected
abnormalities at VIA, VILI or colposcopy had a colposcopy-
directed biopsy taken, and women whose entire squamocolumnar
junction could not be visualised underwent endocervical curettage.
When liquid-based cytology results became available, all women
with cytologically abnormal lesions (atypical squamous cells of
undetermined significance (ASCUS) or worse) not detected at VIA,
VILI or digital colposcopy, were recalled and had biopsies taken.
Treatment of detected lesions was performed according to local
protocols using loop electrosurgical excision procedures.
Cytology and histology
Liquid-based cytology was performed at CI-CAMS. Slides were
prepared from the CytoRich preserved specimen according to the
manufacturer’s standard protocol (Belinson et al, 2003), and
results classified according to the Bethesda System. At CI-CAMS all
abnormal smears, as well as 10% of normal smears chosen at
random, were reviewed by an experienced cytologist, and cervical
biopsies by a pathologist.
On account of the performance of multiple screening tests and
the especially high proportion of histological confirmation of
abnormal cervical findings at VIA, VILI, digital colposcopy or
liquid-based cytology, cervical abnormalities were defined in the
present study as presence of histologically confirmed cervical
intraepithelial neoplasia (CIN)1 or worse.
HPV detection
Human papillomavirus testing was performed on exfoliated
cervical cells in the Department of Pathology at the Vrije
University Medical Center, Amsterdam, The Netherlands. To that
end DNA was extracted first from the remainder of the CytoRich
sample using a High Pure PCR product Purification Kit according
to the manufacturer’s recommendations (Roche Applied Science,
Mannheim, Germany). b-Globin PCR analysis was performed
firstly to confirm the presence of human DNA in all specimens
(Roda Husman et al, 1995). The overall presence of HPV DNA was
determined by performing a general primer GP5þ/6þ-mediated
PCR, which permits the detection of a broad spectrum of genital
HPV types at the subpicogram level (Jacobs et al, 2000). Human
papillomavirus positivity was assessed by hybridisation of PCR
products in an enzyme immunoassay using two HPV oligoprobe
cocktails that, together, detect the following 44 HPV types: HPV 6,
11, 16, 18, 26, 30, 31, 32, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53,
54, 55, 56, 57, 58, 59, 61, 64, 66, 67, 68, 69, 70, 71 (equivalent to
CP8061), 72, 73, 81 (equivalent to CP8304), 82 (IS39 and MM4
subtypes), 83 (equivalent to MM7), 84 (equivalent to MM8),
cand85, 86, cand89 (equivalent to CP6108) and JC9710. Subsequent
HPV typing was performed by reverse line blot hybridisation of
PCR products, as described previously (van den Brule et al, 2002).
Human papillomavirus types considered high-risk for this
analysis included HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 68, 73 and 82 (Mun ˜oz et al, 2003). All other HPV types were
considered low risk.
Statistical analysis
Odds ratios (ORs) for HPV positivity and corresponding 95%
confidence intervals (CIs) were calculated by means of uncondi-
tional logistic regression equations, adjusted for age (15–24, 25–
34, 35–44, 45–54, 55–59 years). The statistical significance of
trends for ORs was assessed by considering the categorical
variables as a continuous variable in the logistic model.
RESULTS
Of 744 married women who provided cervical cell samples, nine
had inadequate cytology results and 73 had b-globin-negative
samples, leaving 662 women with valid cytology and HPV results.
Among them, 68 (10.3%) had histologically confirmed cervical
abnormalities, including 39 CIN1, 16 CIN2, 12 CIN3 and one
squamous cell carcinoma.
The prevalence of any HPV type was 14.8% (60.3% and 9.6%
among women with and without cervical abnormalities, respec-
tively, Table 1). The corresponding prevalences age-standardised
to the world population were 14.2% overall, and 8.9% among those
without cervical abnormalities. In total, 68 women had single-type
and 30 had multiple-type infections. In all, 24 individual HPV
types were identified.
High-risk HPV types were substantially more frequent (12.2% of
all women) than low-risk types (3.8%). The most common types in
either single- or multiple-type infections were HPV16 (5.7%), 58
(3.2%), 52 (1.2%), 33 (1.2%), 42 (a low-risk type, 1.1%), but HPV
type distribution varied by the presence of cervical abnormalities.
High-risk HPV types were found in 54.4% of women with cervical
abnormalities and in 11 out of 12 (91.7%) women with CIN3. The
only woman identified with squamous cell carcinoma was HPV16
positive.
Figure 1 and Table 2 show the prevalence of HPV (any type,
high- and low-risk types, separately) by age group. No significant
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for high-risk HPV types. Low-risk HPV types were found very
rarely among women younger than 35 years, but their frequency
increased significantly with age (P for trend¼0.03). For both high-
risk and low-risk types, lowest prevalence was found in the 25–34
year age group. Table 2 also shows the association between the
Table 1 Prevalence of various HPV types by presence of cervical abnormalities and overall among 662 women. Shanxi Province, China, 2004
Cervical abnormalities
Absent Present
a Total
HPV types Single Multiple Total (%) Single Multiple Total (%) Single Multiple Total (%)
Negative    537 (90.4)    27 (39.7)    564 (85.2)
Positive
Any 42 15 57 (9.6) 26 15 41 (60.3)
b 68 30 98 (14.8)
High risk 31 13 44 (7.4) 23 14 37 (54.4) 54 27 81 (12.2)
Low risk 10 6 16 (2.7) 2 7 9 (13.2) 12 13 25 (3.8)
X 1 0 1 (0.2) 1 0 1 (1.5) 2 0 2 (0.3)
High risk
16 10 8 18 (3.0) 14 6 20 (29.4) 24 14 38 (5.7)
58 7 4 11 (1.9) 4 6 10 (14.7) 11 10 21 (3.2)
52 3 2 5 (0.8) 1 2 3 (4.4) 4 4 8 (1.2)
33 1 2 3 (0.5) 3 2 5 (7.4) 4 4 8 (1.2)
18 3 0 3 (0.5) 0 2 2 (2.9) 3 2 5 (0.8)
56 1 3 4 (0.7) 0 1 1 (1.5) 1 4 5 (0.8)
39 1 2 3 (0.5) 0 1 1 (1.5) 1 3 4 (0.6)
51 1 2 3 (0.5) 0 1 1 (1.5) 1 3 4 (0.6)
45 1 1 2 (0.3) 0 2 2 (2.9) 1 3 4 (0.6)
31 3 0 3 (0.5) 0 0 0 3 0 3 (0.5)
59 0 0 0 1 1 2 (2.9) 1 1 2 (0.3)
68 0 0 0 0 1 1 (1.5) 0 1 1 (0.2)
82 0 0 0 0 1 1 (1.5) 0 1 1 (0.2)
Low-risk
42 1 0 1 (0.2) 0 6 6 (8.8) 1 6 7 (1.1)
66 3 1 4 (0.7) 1 0 1 (1.5) 4 1 5 (0.8)
6 2 1 3 (0.5) 0 0 0 2 1 3 (0.5)
40 0 3 3 (0.5) 0 0 0 0 3 3 (0.5)
67 2 0 2 (0.3) 0 1 1 (1.5) 2 1 3 (0.5)
43 1 1 2 (0.3) 0 0 0 1 1 2 (0.3)
53 0 1 1 (0.2) 1 0 1 (1.5) 1 1 2 (0.3)
44 1 0 1 (0.2) 0 0 0 1 0 1 (0.2)
54 0 1 1 (0.2) 0 0 0 0 1 1 (0.2)
55 0 0 0 0 1 1 (1.5) 0 1 1 (0.2)
64 0 1 1 (0.2) 0 0 0 0 1 1 (0.2)
aIncludes all histologically confirmed cervical intraepithelial neoplasia (CIN)1 and worse;
bAmong 12 women with CIN3, six were positive for HPV16, one for HPV58, one each
for HPV16 and 45, HPV16 and 68, HPV45 and 52, HPV51 and 59; one woman with squamous cell carcinoma was HPV16 positive.
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Figure 1 Age-specific prevalence of cervical HPV DNA and corresponding 95% CI. Shanxi Province, China, 2004.
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Positivity for high-risk HPV types was strongly associated with
increasing cervical lesion severity (OR for CIN3 vs normal¼136;
95% CI: 17.2–1082). Positivity for low-risk HPV types was
associated with CIN1 and CIN2, but not CIN3 (Table 2).
Table 3 shows the relationship between HPV positivity and
various characteristics of study women after adjustment for age. No
significant association was found between HPV positivity and
education level, age at first sexual intercourse, lifetime number of
sexual partners, husband’s extramarital sexual relationships, age at
menarche or menopause, number of births, or the use of the two most
widespread contraceptive methods in the study area (i.e. intrauterine
device and tubal ligation). Only 17.7% of study women reported two
or more sexual partners, and 24.2% reported sexual debut before
age 19 years. No significant associations arose when we evaluated
correlates of high-risk HPV positivity only (data not shown).
Other characteristics that were examined and found not to be
associated with HPV positivity included multiple marriages (50
women, OR¼0.4; 95% CI: 0.2–1.3), being a widow (24 women,
OR¼1.1; 95% CI: 0.3–3.2), history of spontaneous abortion (98
women, OR¼0.9; 95% CI: 0.5–1.7), and induced abortion (241
women, OR¼0.8; 95% CI: 0.5–1.2). No study woman reported
divorce or cigarette smoking. Use of oral contraceptives and
condom was rare (21 and 14 women, respectively) and was
associated with ORs of 2.0 (95% CI: 0.7–5.4) and 0.5 (95% CI: 0.1–
3.7), respectively. Inflammation and/or infection upon colposcopy
was found in 55% of women, but was not significantly associated
with HPV infection (OR 1.3, 95% CI: 0.8–2.0). In all, 64 women
reported to have had at least one previous cytological smear (OR
for HPV positivity¼0.5; 95% CI: 0.2–1.2, data not shown).
DISCUSSION
Relative to previous population-based surveys of HPV worldwide,
noteworthy findings from Shanxi Province, China, include a high
prevalence of HPV infection, a marked predominance of HPV16
among HPV-positive women, and the lack of an observable decline
in HPV prevalence with increasing age.
Age-standardised HPV prevalence in Shanxi Province was found
to be similar to that found in other high-risk areas for cervical
cancer studied by IARC using the same HPV testing protocol in
Latin America (Molano et al, 2002; Matos et al, 2003; Ferreccio
et al, 2004) and India (Franceschi et al, 2005), although lower than
in some areas of sub-Saharan Africa (Thomas et al, 2004). In
contrast to previous studies in high-resource countries (Peto et al,
2004), however, no decline of HPV prevalence was seen with
increasing age, and highest HPV prevalence was found among
middle-aged women. This age pattern is similar to the flat age
curve seen in rural India (Franceschi et al, 2005) and Africa
(Thomas et al, 2004; Clifford & Franceschi, 2005).
Large cohort studies in Colombia (Mun ˜oz et al, 2004) and Costa
Rica (Castle et al, 2005) have shown that new HPV infection in
middle-aged women is not rare, but, Castle et al (2005) suggested a
stronger role for HPV persistence than acquisition of new infection
in determining HPV prevalence in women over 45 years of
age. Thus, high HPV prevalence in middle-aged women in Shanxi
Province may indicate a relative lack of clearance or high
frequency of reactivation of HPV infection. Furthermore, in
conservative societies like rural China, it is likely that young
women are not more frequently exposed to HPV than middle-aged
women. Indeed, we observed no differences in indicators of sexual
behaviour (e.g. age at first sexual intercourse (19.4 and 19.0 years,
respectively) or frequency of husband’s extramarital sexual
relationships (15.2 and 14.0%, respectively)) among women aged
under 25 years and over 45 years.
Our survey is the first population-based study in China to assess
HPV type-specific prevalence across a broad age-range of women.
It showed that HPV16 is the most frequently found type in Shanxi
Province, affecting 38.8% of HPV-positive women. The correspond-
ing percentages in other IARC HPV prevalence surveys in different
continents were 32.6% in Europe, 22.5% in Asia, 22.0% in Latin
America, and 12.2% in Africa (Clifford et al, 2005), making the
proportion of HPV16-positive women in our present population-
based study among the highest recorded worldwide. In a study of
809 cervical cancer cases from four areas in China, a relatively high
proportion (66.9%) were positive for HPV16 (Lo et al, 2002).
HPV58 was the second most common HPV type in Shanxi
Province, and was found in one quarter of all HPV-positive
cervical abnormalities, confirming the importance of HPV58
infection in Asia (Chan, 2005). Studies of cervical cancer cases
from China have reported varying HPV58 prevalence between 2.9
and 27.5% (Clifford et al, 2003). The distribution of other
commonly identified HPV types in Shanxi Province (e.g. HPV18,
Table 2 Detection of cervical HPV any type, high-risk types and low-risk types according to age and the presence of cervical abnormalities among 662
women. Shanxi Province, China, 2004
HPV positive
Any High risk
a Low risk
b
Total no. No. % OR (95% CI)
c No. % OR (95% CI)
c No. % OR (95% CI)
c
Age (years)
15–24 45 6 13.3 1.9 (0.7–5.3) 5 11.1 1.7 (0.6–5.0) 1 2.2 1.3 (0.1–12.7)
25–34
d 173 13 7.5 1 12 6.9 1 3 1.7 1
35–44 176 36 20.5 3.2 (1.6–6.2) 30 17.1 2.8 (1.4–5.6) 7 4.0 2.3 (0.6–9.2)
45–54 177 30 17.0 2.5 (1.3–5.0) 25 14.1 2.2 (1.1–4.5) 7 4.0 2.3 (0.6–9.2)
55–59 91 13 14.3 2.1 (0.9–4.6) 9 9.9 1.5 (0.6–3.6) 7 7.7 4.7 (1.2–18.7)
p for trend ¼0.11 ¼0.34 ¼0.03
Presence of cervical abnormalities
Normal
d 594 57 9.6 1 44 7.4 1 16 2.7 1
CIN1 39 18 46.2 7.6 (3.7–15.4) 16 41.0 8.6 (4.1–18.0) 6 15.4 5.5 (2.0–15.5)
CIN2 16 11 68.8 22.0 (7.2–67.4) 9 56.3 16.8 (5.8–48.4) 3 18.8 8.8 (2.2–35.1)
CIN3 and worse 13 12 92.3 102 (12.8–803) 12 92.3 136 (17.2–1082) 0 0 0 (0–11.4)
p for trend o0.001 o0.001 ¼0.007
aIncludes that in multiple infections with low-risk types.
bIncludes that in multiple infections with high-risk types.
cAdjusted for age (10-year groups);
dReference category.
OR¼odds ratio; CI¼confidence interval; CIN¼cervical intraepithelial neoplasia.
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analysis of IARC HPV prevalence surveys (Clifford et al, 2005).
No questionnaire-based information, including sexual habit
indicators, reproductive and menstrual characteristics, oral contra-
ceptive or condom use, showed any significant associations with
HPV positivity. This may be partly related to the fact that this study
took place in a rather homogenous, low-income rural population.
Our present study has strengths and limitations. Among the
former, the use of highly sensitive PCR assays and enrolment of
a representative sample of the married female population. A high
proportion of histological confirmation was also an asset, allowing
a clear distinction between the similar potential of high-risk and
low-risk types to induce CIN1 and 2 but not CIN3. The main
limitation of the present study was that only approximately half of
the initially invited population had cells collected for HPV testing.
Of the nonparticipants that were interviewed, a large proportion
was unmarried. Indeed HPV testing was offered only to married
women, who were expected to be a reasonably good proxy of
sexually active women in this conservative society. Furthermore, as
HPV infection is asymptomatic and does not show, contrary to
cervical cancer (Rajkumar et al, 2003), any strong socio-economic
gradient, it is unlikely that participation was related to women’s
HPV infection status.
In conclusion, our study allowed the disclosure of a high
prevalence of HPV and an age-specific prevalence curve that is in
sharp contrast with the peak in HPV prevalence below age 25 years
observed in Europe (de Sanjose ´ et al, 2003; Peto et al, 2004; Ronco
et al, 2005) and North America (Bauer et al, 1993).
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Table 3 Detection of cervical HPV DNA according to selected characteristics among 662 women. Shanxi, China, 2004
HPV DNA positive
Characteristics No. of women No. % Age-adjusted OR (95% CI)
a
Education
Illiterate or primary
b 247 37 15.0 1
Junior high school 336 51 15.2 1.0 (0.6–1.7)
Senior high school and above 79 10 12.7 0.8 (0.3–1.7)
p for trend¼0.64
Age at first sexual intercourse (years)
X21
b 209 34 16.3 1
19–20 293 47 16.0 0.9 (0.6–1.5)
p18 160 17 10.6 0.5 (0.2–1.0)
p for trend¼0.08
Lifetime number of sexual partners
1
b 545 85 15.6 1
X2 117 13 11.1 0.7 (0.3–1.2)
Husband’s extramarital sexual relationships
No
b 583 88 15.1 1
Yes 79 10 12.7 0.8 (0.4–1.7)
Age at menarche (years)
p14
b 235 36 15.3 1
15–16 225 32 14.2 0.7 (0.4–1.2)
X17 202 30 14.9 0.7 (0.4–1.2)
p for trend¼0.18
Menopausal status
c
Premenopause
b 90 18 20.0 1
Menopause o50 years old 106 17 16.0 0.7 (0.3–1.7)
Menopause X50 years old 72 8 11.1 0.5 (0.2–1.3)
No. of births
0 15 1 6.7 0.7 (0.1–5.7)
1
b 154 16 10.4 1
2 336 54 16.1 1.3 (0.6–2.7)
X3 157 27 17.2 1.5 (0.6–3.7)
p for trend¼0.31
Intrauterine device use
Never
b 308 44 14.3 1
Ever 354 54 15.3 1.1 (0.7–1.7)
Tubal ligation
No
b 284 33 11.6 1
Yes 378 65 17.2 1.4 (0.8–2.3)
aAdjusted for age (10-year groups);
bReference category;
cWomen X45 years only (n¼268). OR¼odds ratio; CI¼confidence interval.
HPV prevalence in China
M Dai et al
100
British Journal of Cancer (2006) 95(1), 96–101 & 2006 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yREFERENCES
Anh PTH, Hieu NT, Herrero R, Vaccarella S, Smith JS, Thuy NT, Nga NH,
Duc NB, Ashley R, Snijders PJF, Meijer CJLM, Mun ˜oz N, Parkin DM,
Franceschi S (2003) Human papillomavirus infection among women in
South and North Vietnam. Int J Cancer 104: 213–220
Bauer HM, Hildesheim A, Schiffman MH, Glass AG, Rush BB, Scott DR,
Cadell DM, Kurman RJ, Manos MM (1993) Determinants of genital
human papillomavirus infection in low-risk women in Portland, Oregon.
Sex Transm Dis 20: 274–278
Belinson JL, Qiao YL, Pretorius RG, Zhang WH, Rong SD, Huang MN, Zhao
FH, Wu LY, Ren SD, Huang RD, Washington MF, Pan QJ, Li L, Fife D
(2003) Shanxi Province cervical cancer screening study II: self-sampling
for high-risk human papillomavirus compared to direct sampling for
human papillomavirus and liquid based cervical cytology. Int J Gynecol
Cancer 13: 819–826
Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti
MC, Sherman ME, Wacholder S, Tarone R, Burk RD (2005) A prospective
study of age trends in cervical human papillomavirus acquisition and
persistence in Guanacaste, Costa Rica. J Infect Dis 191: 1808–1816
Chan PKS (2005) Epidemiology of human papillomavirus in Asia: do HPV-
52 and HPV-58 play a special role? Papillomavirus Rep 16: 265–271
Clifford GM, Smith JS, Plummer M, Mun ˜oz N, Franceschi S (2003) Human
papillomavirus types in invasive cervical cancer worldwide: a meta-
analysis. Br J Cancer 88: 63–73
Clifford GM, Franceschi S (2005) HPV in sub-Saharan Africa (editorial).
Papillomavirus Rep 16: 322–326
Clifford GM, Gallus S, Herrero R, Mun ˜oz N, Snijders PJF, Vaccarella S, Anh
PTH, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G,
de Sanjose ´ S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer
CJLM, Franceschi S (2005) Worldwide distribution of human papillo-
mavirus types in cytologically normal women in the International
Agency for Research on Cancer HPV prevalence surveys: a pooled
analysis. Lancet 366: 991–998
de Sanjose ´ S, Almirall R, Lloveras B, Font R, Diaz M, Mun ˜oz N, Catala I,
Meijer CJLM, Snijders PJF, Herrero R, Bosch FX (2003) Cervical human
papillomavirus infection in the female population in Barcelona, Spain.
Sex Transm Dis 30: 788–793
Ferreccio C, Prado RB, Luzoro AV, Ampuero SL, Snijders PJF, Meijer
CJLM, Vaccarella S, Jara AT, Puschel KI, Robles SC, Herrero R,
Franceschi S, Ojeda JM (2004) Population-based prevalence and age
distribution of human papillomavirus among women in Santiago, Chile.
Cancer Epidemiol Biomarkers Prev 13: 2271–2276
Franceschi S, Rajkumar R, Snijders PJF, Arslan A, Mahe ´ C, Plummer M,
Sankaranarayanan R, Cherian J, Meijer CJLM, Weiderpass E (2005)
Papillomavirus infection in rural women in southern India. Br J Cancer
92: 601–606
Jacobs MV, Walboomers JM, Snijders PJF, Voorhorst FJ, Verheijen RH,
Fransen-Daalmeijer N, Meijer CJLM (2000) Distribution of 37 mucoso-
tropic HPV types in women with cytologically normal cervical smears:
the age-related patterns for high-risk and low-risk types. Int J Cancer 87:
221–227
Lazcano-Ponce E, Herrero R, Mun ˜oz N, Cruz A, Shah KV, Alonso P,
Herna ´ndez P, Salmeron J, Herna ´ndez M (2001) Epidemiology of HPV
infection among Mexican women with normal cervical cytology. Int J
Cancer 91: 412–420
Lo KW, Wong YF, Chan MK, Li JC, Poon JS, Wang VW, Zhu SN, Zhang
TM, He ZG, Wu QL, Li GD, Tam JS, Kahn T, Lam P, Cheung TH, Chung
TK (2002) Prevalence of human papillomavirus in cervical cancer: a
multicenter study in China. Int J Cancer 100: 327–331
Matos E, Loria D, Amestoy G, Herrera L, Prince MA, Moreno J, Krunfly C,
van den Brule AJ, Meijer CJLM, Mun ˜oz N, Herrero R, Proyecto
Concordia Collaborative Group (2003) Prevalence of human papilloma-
virus infection among women in Concordia, Argentina: a population-
based study. Sex Transm Dis 30: 593–599
Molano M, Posso H, Weiderpass E, van den Brule AJ, Ronderos M,
Franceschi S, Meijer CJLM, Arslan A, Mun ˜oz N (2002) Prevalence and
determinants of HPV infection among Colombian women with normal
cytology. Br J Cancer 87: 324–333
Mun ˜oz N, Bosch FX, de Sanjose ´ S, Herrero R, Castellsague ´ X, Shah KV,
Snijders PJF, Meijer CJLM (2003) Epidemiologic classification of human
papillomavirus types associated with cervical cancer. N Engl J Med 348:
518–527
Mun ˜oz N, Mendez F, Posso H, Molano M, van den Brule AJ, Ronderos M,
Meijer CJLM, Mun ˜oz A, for the Instituto Nacional de Cancerologı ´a HPV
Study Group (2004) Incidence, duration, and determinants of cervical
human papillomavirus infection in a cohort of Colombian women with
normal cytological results. J Infect Dis 190: 2077–2087
Parkin DM, Whelan SL, Ferlay J, Thomas DB, Teppo L (2002) Cancer
Incidence in Five Continents, Vol. VIII. IARC Scientific Publications No.
155 IARC Press: Lyon
Peto J, Gilham C, Deacon J, Taylor C, Evans C, Binns W, Haywood M,
Elanko N, Coleman D, Yule R, Desai M (2004) Cervical HPV infection
and neoplasia in a large population-based prospective study: the
Manchester cohort. Br J Cancer 91: 942–953
Rajkumar T, Franceschi S, Vaccarella S, Gajalakshmi V, Sharmila A,
Snijders PJF, Mun ˜oz N, Meijer CJLM, Herrero R (2003) Role of paan
chewing and dietary habits in cervical carcinoma in Chennai, India. Br J
Cancer 88: 1388–1393
Roda Husman AM, Snijders PJF, Stel HV, van den Brule AJ, Meijer CJLM,
Walboomers JM (1995) Processing of long-stored archival cervical
smears for human papillomavirus detection by the polymerase chain
reaction. Br J Cancer 72: 412–417
Ronco G, Ghisetti V, Segnan N, Snijders PJF, Gillio-Tos A, Meijer CJ,
Merletti F, Franceschi S (2005) Prevalence of human papillomavirus
infection in women in Turin, Italy. Eur J Cancer 41: 297–305
Shin HR, Franceschi S, Vaccarella S, Roh JW, Ju YH, Oh JK, Kong HJ,
Rha SH, Jung SI, Kim JI, Jung KY, van Doorn LJ, Quint W (2004)
Prevalence and determinants of genital infection with papillomavirus, in
female and male university students in Busan, South Korea. J Infect Dis
190: 468–476
Shin HR, Lee DH, Herrero R, Smith JS, Vaccarella S, Hong SH, Jung KY,
Kim HH, Park UD, Cha HS, Park S, Touze A, Mun ˜oz N, Snijders PJF,
Meijer CJLM, Coursaget P, Franceschi S (2003) Prevalence of human
papillomavirus infection in women in Busan, South Korea. Int J Cancer
103: 413–421
Sukvirach S, Smith JS, Tunsakul S, Mun ˜oz N, Kesararat V, Opasatian O,
Chichareon S, Kaenploy V, Ashley R, Meijer CJLM, Snijders PJF,
Coursaget P, Franceschi S, Herrero R (2003) Population-based human
papillomavirus prevalence in Lampang and Songkla, Thailand. J Infect
Dis 187: 1246–1256
Thomas JO, Herrero R, Omigbodun AA, Ojemakinde K, Ajayi IO, Fawole A,
Oladepo O, Smith JS, Arslan A, Mun ˜oz N, Snijders PJF, Meijer CJLM,
Franceschi S (2004) Prevalence of papillomavirus infection in women in
Ibadan, Nigeria: a population-based study. Br J Cancer 90: 638–645
van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJLM,
Snijders PJF (2002) GP5+/6+ PCR followed by reverse line blot analysis
enables rapid and high-throughput identification of human papilloma-
virus genotypes. J Clin Microbiol 40: 779–787
Yang L, Huangpu XM, Zhang SW, Lu FZ, Sun XD, Sun J, Mu R, Li LD, Qiao
YL (2003a) Changes of mortality rate for cervical cancer during 1970’s
and 1990’s periods in China. Acta Acad Med Sin 25: 386–390
Yang L, Parkin DM, Li L, Chen Y (2003b) Time trends in cancer mortality
in China: 1987–1999. Int J Cancer 106: 771–783
Zhao FH, Forman MR, Belinson J, Shen YH, Graubard BI, Patel AC, Rong
SD, Pretorius RG, Qiao YL (2006) Risk factors for HPV infection and
cervical cancer among unscreened women in a high-risk rural area of
China. Int J Cancer 118: 442–448
HPV prevalence in China
M Dai et al
101
British Journal of Cancer (2006) 95(1), 96–101 & 2006 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
y